| 前收盘价格 | 32.75 |
| 收盘价格 | 31.60 |
| 成交量 | 110,400 |
| 平均成交量 (3个月) | 9,137,176 |
| 市值 | 53,328,617,472 |
| 预期市盈率 (P/E Forward) | 476.19 |
| 价格/销量 (P/S) | 6.48 |
| 股市价格/股市净资产 (P/B) | 4.54 |
| 52周波幅 | |
| 利润日期 | 18 Mar 2025 - 24 Mar 2025 |
| 营业毛利率 | -17.18% |
| 营业利益率 (TTM) | -10.94% |
| 稀释每股收益 (EPS TTM) | -0.870 |
| 季度收入增长率 (YOY) | 46.30% |
| 总债务/股东权益 (D/E MRQ) | 26.95% |
| 流动比率 (MRQ) | 2.68 |
| 营业现金流 (OCF TTM) | 555.07 M |
| 杠杆自由现金流 (LFCF TTM) | -176.40 M |
| 资产报酬率 (ROA TTM) | -4.18% |
| 股东权益报酬率 (ROE TTM) | -11.04% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (HK) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | INNOVENT BIO | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -4.0 |
| 平均 | 0.50 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| INNOVENT BIO | 53 B | - | - | 4.54 |
| AKESO | 55 B | - | - | 9.50 |
| BEIGENE | 195 B | - | - | 6.93 |
| WUXI BIO | 82 B | - | 29.13 | 1.87 |
| SINO BIOPHARM | 52 B | 1.92% | 22.08 | 1.48 |
| PHARMARON | 46 B | 1.60% | 12.70 | 1.66 |
|
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Growth |
| 内部持股比例 | 6.78% |
| 机构持股比例 | 45.93% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合